Results 71 to 80 of about 2,249 (191)

Dupilumab: A new paradigm for the treatment of allergic diseases [PDF]

open access: yes, 2018
Moderate and severe forms of allergic diseases such as atopic dermatitis and asthma are a challenge for clinicians. In these conditions, which severely affect the quality of life of the patient and frequently have associated allergic comorbidities, the ...
Dávila, Ignacio, Sastre, Joaquín
core   +2 more sources

Cutaneous T‐cell lymphomas and dupilumab for atopic dermatitis: A systematic review and expert consensus

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review (51 studies; 547 patients) indicates dupilumab may unmask/worsen CTCL (mainly MF/SS). A French Delphi consensus recommends rigorous diagnostic workup, avoiding dupilumab in confirmed CTCL, discontinuing upon diagnosis, and favouring methotrexate or phototherapy.
Florent Amatore   +8 more
wiley   +1 more source

Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This multicentre, observational cohort study in adults and adolescents with atopic dermatitis found that dupilumab treatment provides a higher probability of achieving the treatment targets EASI ≤ 7 and NRS‐pruritus ≤ 4 compared with tralokinumab treatment. Absolute EASI and NRS‐pruritus differences were small among responders.
Lian F. van der Gang   +18 more
wiley   +1 more source

Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma [PDF]

open access: yes, 2016
Severe asthma represents a major unmet clinical need. Eosinophilic inflammation persists in the airways of many patients with uncontrolled asthma, despite high-dose inhaled corticosteroid therapy. Suppressors of cytokine signalling (SOCS) are a family of
Arron, Joseph R   +9 more
core   +2 more sources

Treatment‐associated phenotype switching between psoriasis and atopic dermatitis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
This international, multicentre real‐world study of 148 patients’ documents treatment‐associated, bidirectional phenotype switching between psoriasis and atopic dermatitis. Psoriasis‐to‐eczematous switches occurred predominantly with IL‐17 and IL‐23 inhibitors, whereas AD‐to‐psoriasiform switches occurred exclusively during treatment with biologic ...
Tiago Torres   +28 more
wiley   +1 more source

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

open access: yesDermatology and Therapy, 2023
Introduction Atopic dermatitis (AD) is a chronic inflammatory skin disorder with limited treatment options for adolescents with moderate-to-severe disease.
Amy S. Paller   +14 more
doaj   +1 more source

Chinese Position Paper on Biologic Therapy for Allergic Rhinitis

open access: yesAllergy, Volume 81, Issue 5, Page 1354-1369, May 2026.
ABSTRACT Allergic rhinitis (AR) is a common, persistent nasal disorder that poses significant public health challenges worldwide. Current treatment options frequently fail to achieve adequate symptom control in a substantial subset of patients. Over the past two decades, biologic therapies that target type 2 inflammatory pathways have been used to ...
Yuan Zhang   +37 more
wiley   +1 more source

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis

open access: yesDermatology and Therapy, 2023
Introduction Lebrikizumab and dupilumab are monoclonal antibodies approved for treating moderate-to-severe atopic dermatitis (AD). Both have demonstrated efficacy and safety over the 16-week SOLOs and ADvocate trials.
Kim Rand   +4 more
doaj   +1 more source

Preferential Generation of 15-HETE-PE Induced by IL-13 Regulates Goblet Cell Differentiation in Human Airway Epithelial Cells [PDF]

open access: yes, 2017
Type 2–associated goblet cell hyperplasia and mucus hypersecretion are well known features of asthma. 15-Lipoxygenase-1 (15LO1) is induced by the type 2 cytokine IL-13 in human airway epithelial cells (HAECs) in vitro and is increased in fresh asthmatic ...
Aldrovandi, Maceler   +10 more
core   +2 more sources

Mixed Signals: T Cells as Architects of IgE Immunity

open access: yesImmunological Reviews, Volume 339, Issue 1, May 2026.
ABSTRACT Food allergen‐specific IgE can cause significant pathology, yet the pathways that generate pathogenic, high‐affinity IgE remain incompletely understood. Increasing evidence suggests that IgE responses arise from the integration of multiple, and sometimes opposing, T cell–derived cues.
Abigail L. Tierney   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy